 Brigitte Frohnert
Concepts (284)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 49 | 2026 | 3937 | 3.430 |
Why?
| | Islets of Langerhans | 22 | 2026 | 847 | 2.860 |
Why?
| | Autoimmunity | 24 | 2026 | 933 | 2.460 |
Why?
| | Autoantibodies | 30 | 2026 | 1509 | 1.610 |
Why?
| | Celiac Disease | 5 | 2022 | 311 | 0.850 |
Why?
| | Genetic Predisposition to Disease | 11 | 2023 | 2399 | 0.840 |
Why?
| | Protein Carbonylation | 3 | 2015 | 57 | 0.810 |
Why?
| | Insulins | 1 | 2023 | 39 | 0.730 |
Why?
| | Insulin Resistance | 6 | 2013 | 1244 | 0.710 |
Why?
| | Oxidative Stress | 3 | 2013 | 1359 | 0.690 |
Why?
| | Child, Preschool | 30 | 2026 | 11868 | 0.640 |
Why?
| | Child | 44 | 2026 | 22739 | 0.610 |
Why?
| | Adipocytes | 4 | 2013 | 223 | 0.600 |
Why?
| | Insulin Infusion Systems | 3 | 2023 | 480 | 0.560 |
Why?
| | Bone Density | 3 | 2020 | 487 | 0.540 |
Why?
| | HLA-D Antigens | 1 | 2017 | 30 | 0.520 |
Why?
| | Insulin | 9 | 2023 | 2516 | 0.510 |
Why?
| | Hypoglycemic Agents | 5 | 2026 | 1399 | 0.480 |
Why?
| | Disease Progression | 11 | 2026 | 2865 | 0.470 |
Why?
| | Infusions, Subcutaneous | 1 | 2015 | 23 | 0.460 |
Why?
| | Fatty Acids, Nonesterified | 2 | 2013 | 154 | 0.450 |
Why?
| | Infant | 19 | 2026 | 10090 | 0.440 |
Why?
| | Equipment Failure | 1 | 2015 | 115 | 0.440 |
Why?
| | Genotype | 8 | 2026 | 1857 | 0.440 |
Why?
| | Models, Genetic | 1 | 2017 | 527 | 0.430 |
Why?
| | Prospective Studies | 15 | 2026 | 8075 | 0.430 |
Why?
| | Adolescent | 28 | 2026 | 22573 | 0.420 |
Why?
| | Blood Glucose | 5 | 2026 | 2344 | 0.410 |
Why?
| | Polymorphism, Single Nucleotide | 5 | 2026 | 2181 | 0.400 |
Why?
| | Blood Glucose Self-Monitoring | 4 | 2025 | 701 | 0.400 |
Why?
| | Humans | 64 | 2026 | 145763 | 0.370 |
Why?
| | Lipid Peroxidation | 1 | 2013 | 168 | 0.370 |
Why?
| | Ascorbic Acid | 2 | 2026 | 184 | 0.350 |
Why?
| | Adiposity | 3 | 2013 | 532 | 0.350 |
Why?
| | DNA Methylation | 3 | 2023 | 690 | 0.350 |
Why?
| | Subcutaneous Fat, Abdominal | 1 | 2011 | 15 | 0.340 |
Why?
| | Biomarkers | 5 | 2023 | 4302 | 0.330 |
Why?
| | Fasting | 2 | 2010 | 279 | 0.320 |
Why?
| | Case-Control Studies | 10 | 2023 | 3634 | 0.310 |
Why?
| | Male | 39 | 2026 | 73003 | 0.310 |
Why?
| | Obesity | 3 | 2013 | 3118 | 0.300 |
Why?
| | Metabolomics | 1 | 2015 | 733 | 0.300 |
Why?
| | Female | 40 | 2026 | 79035 | 0.300 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2019 | 48 | 0.280 |
Why?
| | Cystic Fibrosis | 3 | 2012 | 1163 | 0.240 |
Why?
| | Mitochondria | 1 | 2013 | 992 | 0.230 |
Why?
| | Inflammation | 2 | 2017 | 2883 | 0.230 |
Why?
| | Glucose Tolerance Test | 4 | 2026 | 361 | 0.230 |
Why?
| | Macrophages | 1 | 2013 | 1507 | 0.230 |
Why?
| | HLA Antigens | 1 | 2026 | 240 | 0.220 |
Why?
| | Diabetes Mellitus, Type 2 | 5 | 2023 | 2602 | 0.210 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 971 | 0.210 |
Why?
| | Oxylipins | 2 | 2023 | 47 | 0.210 |
Why?
| | HLA-DR4 Antigen | 3 | 2021 | 74 | 0.210 |
Why?
| | HLA-DR3 Antigen | 3 | 2021 | 76 | 0.200 |
Why?
| | Longitudinal Studies | 6 | 2026 | 2967 | 0.200 |
Why?
| | Cardiovascular Diseases | 2 | 2013 | 2191 | 0.200 |
Why?
| | Membrane Transport Proteins | 3 | 1999 | 154 | 0.200 |
Why?
| | Risk Factors | 12 | 2026 | 10917 | 0.200 |
Why?
| | Carrier Proteins | 4 | 2000 | 729 | 0.190 |
Why?
| | HLA-DR Antigens | 3 | 2022 | 220 | 0.190 |
Why?
| | GTP-Binding Proteins | 2 | 2021 | 153 | 0.190 |
Why?
| | Transglutaminases | 2 | 2021 | 159 | 0.180 |
Why?
| | Cohort Studies | 7 | 2026 | 6032 | 0.180 |
Why?
| | Technology | 1 | 2023 | 97 | 0.180 |
Why?
| | Vitamin D | 1 | 2026 | 404 | 0.180 |
Why?
| | Glutathione Transferase | 2 | 2013 | 92 | 0.180 |
Why?
| | Growth Charts | 1 | 2022 | 20 | 0.180 |
Why?
| | Young Adult | 8 | 2026 | 14251 | 0.160 |
Why?
| | Diet, Carbohydrate-Restricted | 1 | 2021 | 38 | 0.160 |
Why?
| | Body Height | 1 | 2022 | 203 | 0.160 |
Why?
| | Diet, Ketogenic | 1 | 2021 | 39 | 0.160 |
Why?
| | Prediabetic State | 1 | 2023 | 250 | 0.160 |
Why?
| | Glutamate Decarboxylase | 4 | 2022 | 165 | 0.160 |
Why?
| | Mannose | 1 | 2019 | 23 | 0.150 |
Why?
| | Adenosine Diphosphate | 1 | 2019 | 83 | 0.150 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2026 | 992 | 0.150 |
Why?
| | Inservice Training | 1 | 2020 | 118 | 0.150 |
Why?
| | Glucose Intolerance | 2 | 2010 | 142 | 0.150 |
Why?
| | Osteoporotic Fractures | 1 | 2020 | 62 | 0.140 |
Why?
| | Butyrates | 1 | 2019 | 66 | 0.140 |
Why?
| | Diet | 1 | 2026 | 1278 | 0.140 |
Why?
| | Insulin-Secreting Cells | 1 | 2023 | 392 | 0.140 |
Why?
| | Fibrinogen | 1 | 2019 | 180 | 0.140 |
Why?
| | Membrane Proteins | 3 | 1999 | 1166 | 0.140 |
Why?
| | Mammals | 1 | 2000 | 286 | 0.140 |
Why?
| | Fatty Acids | 3 | 2000 | 457 | 0.140 |
Why?
| | Thiazolidinediones | 1 | 1999 | 143 | 0.130 |
Why?
| | Mentors | 1 | 2020 | 217 | 0.130 |
Why?
| | Mass Spectrometry | 1 | 2021 | 731 | 0.130 |
Why?
| | Interprofessional Relations | 1 | 2020 | 276 | 0.130 |
Why?
| | Cross-Sectional Studies | 5 | 2020 | 5922 | 0.130 |
Why?
| | Discriminant Analysis | 1 | 2017 | 35 | 0.130 |
Why?
| | Triglycerides | 1 | 2000 | 520 | 0.130 |
Why?
| | Mentoring | 1 | 2020 | 166 | 0.130 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 1999 | 209 | 0.130 |
Why?
| | Absorptiometry, Photon | 2 | 2020 | 277 | 0.130 |
Why?
| | Osteoporosis | 1 | 2020 | 239 | 0.130 |
Why?
| | Polymorphism, Genetic | 1 | 2019 | 615 | 0.120 |
Why?
| | Models, Statistical | 1 | 2021 | 672 | 0.120 |
Why?
| | Health Care Costs | 1 | 2020 | 425 | 0.120 |
Why?
| | Family Health | 1 | 2017 | 191 | 0.120 |
Why?
| | HLA-DQ Antigens | 1 | 2017 | 174 | 0.120 |
Why?
| | History, 21st Century | 1 | 2017 | 222 | 0.120 |
Why?
| | Infant, Newborn | 5 | 2022 | 6464 | 0.120 |
Why?
| | Organelle Biogenesis | 1 | 2015 | 14 | 0.120 |
Why?
| | Disease-Free Survival | 1 | 2017 | 770 | 0.110 |
Why?
| | Subcutaneous Fat | 1 | 2015 | 79 | 0.110 |
Why?
| | Guidelines as Topic | 1 | 2017 | 268 | 0.110 |
Why?
| | Proteins | 1 | 2021 | 1023 | 0.110 |
Why?
| | Age of Onset | 1 | 2017 | 557 | 0.110 |
Why?
| | Genetic Testing | 1 | 2018 | 483 | 0.110 |
Why?
| | Hypoglycemia | 1 | 2020 | 480 | 0.110 |
Why?
| | Mass Screening | 2 | 2021 | 1361 | 0.110 |
Why?
| | Proteomics | 1 | 2021 | 1188 | 0.100 |
Why?
| | DNA-Binding Proteins | 2 | 2015 | 1482 | 0.100 |
Why?
| | Gastric Bypass | 1 | 2015 | 126 | 0.100 |
Why?
| | Intestinal Mucosa | 1 | 2000 | 675 | 0.100 |
Why?
| | Aldehyde Reductase | 1 | 2013 | 31 | 0.100 |
Why?
| | Body Mass Index | 2 | 2013 | 2447 | 0.100 |
Why?
| | Transcription Factors | 2 | 2015 | 1736 | 0.100 |
Why?
| | Adult | 8 | 2026 | 40872 | 0.090 |
Why?
| | Muscle Cells | 1 | 2013 | 41 | 0.090 |
Why?
| | Growth Disorders | 1 | 2013 | 89 | 0.090 |
Why?
| | Age Factors | 3 | 2020 | 3346 | 0.090 |
Why?
| | Aldehydes | 1 | 2013 | 140 | 0.090 |
Why?
| | Ultrasonography, Doppler | 1 | 2013 | 126 | 0.090 |
Why?
| | Autoimmune Diseases | 1 | 2017 | 469 | 0.090 |
Why?
| | Models, Biological | 1 | 2019 | 1764 | 0.090 |
Why?
| | Human Growth Hormone | 1 | 2012 | 47 | 0.090 |
Why?
| | Colorado | 4 | 2026 | 4556 | 0.090 |
Why?
| | Glutathione | 1 | 2013 | 370 | 0.090 |
Why?
| | Aldehyde Dehydrogenase, Mitochondrial | 1 | 2011 | 23 | 0.090 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2011 | 28 | 0.080 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2011 | 99 | 0.080 |
Why?
| | Intra-Abdominal Fat | 1 | 2011 | 101 | 0.080 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2011 | 267 | 0.080 |
Why?
| | Sensitivity and Specificity | 3 | 2022 | 2000 | 0.080 |
Why?
| | Diabetic Ketoacidosis | 2 | 2024 | 210 | 0.070 |
Why?
| | United States | 4 | 2022 | 16123 | 0.070 |
Why?
| | Time Factors | 2 | 2017 | 7133 | 0.070 |
Why?
| | Survivors | 1 | 2012 | 523 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1217 | 0.070 |
Why?
| | Glucose | 1 | 2013 | 1048 | 0.070 |
Why?
| | RNA, Messenger | 2 | 2015 | 2805 | 0.060 |
Why?
| | Predictive Value of Tests | 3 | 2019 | 2123 | 0.060 |
Why?
| | Genetic Association Studies | 2 | 2020 | 371 | 0.060 |
Why?
| | Obesity, Morbid | 1 | 2011 | 293 | 0.060 |
Why?
| | Hyperglycemia | 1 | 2010 | 379 | 0.060 |
Why?
| | Overweight | 1 | 2011 | 614 | 0.060 |
Why?
| | Incidence | 2 | 2026 | 2933 | 0.060 |
Why?
| | Fatty Acid Transport Proteins | 3 | 1999 | 22 | 0.050 |
Why?
| | Follow-Up Studies | 3 | 2021 | 5428 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2026 | 172 | 0.050 |
Why?
| | Risk Assessment | 3 | 2020 | 3752 | 0.050 |
Why?
| | C-Peptide | 1 | 2026 | 190 | 0.050 |
Why?
| | Diabetes Mellitus | 1 | 2012 | 1101 | 0.050 |
Why?
| | GTPase-Activating Proteins | 1 | 2023 | 81 | 0.050 |
Why?
| | CpG Islands | 1 | 2023 | 171 | 0.050 |
Why?
| | Finland | 1 | 2022 | 78 | 0.050 |
Why?
| | Seroepidemiologic Studies | 1 | 2023 | 171 | 0.050 |
Why?
| | Germany | 1 | 2022 | 138 | 0.050 |
Why?
| | Social Determinants of Health | 1 | 2026 | 309 | 0.040 |
Why?
| | Prognosis | 3 | 2018 | 4329 | 0.040 |
Why?
| | Mice | 3 | 2013 | 18355 | 0.040 |
Why?
| | Diagnostic Techniques, Radioisotope | 1 | 2021 | 9 | 0.040 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 1 | 2021 | 54 | 0.040 |
Why?
| | Linoleic Acid | 1 | 2021 | 44 | 0.040 |
Why?
| | Immunoglobulin D | 1 | 2021 | 29 | 0.040 |
Why?
| | Arachidonic Acid | 1 | 2021 | 102 | 0.040 |
Why?
| | Serologic Tests | 1 | 2021 | 54 | 0.040 |
Why?
| | Perception | 1 | 2023 | 378 | 0.040 |
Why?
| | Electrochemical Techniques | 1 | 2021 | 55 | 0.040 |
Why?
| | Markov Chains | 1 | 2021 | 132 | 0.040 |
Why?
| | Docosahexaenoic Acids | 1 | 2021 | 88 | 0.040 |
Why?
| | Iodide Peroxidase | 1 | 2020 | 35 | 0.040 |
Why?
| | Animals | 5 | 2013 | 38097 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2021 | 104 | 0.040 |
Why?
| | Glutens | 1 | 2020 | 59 | 0.040 |
Why?
| | Transfection | 2 | 1999 | 927 | 0.040 |
Why?
| | Absorption | 1 | 2000 | 60 | 0.040 |
Why?
| | Coenzyme A Ligases | 1 | 1999 | 15 | 0.040 |
Why?
| | Peroxidase | 1 | 2020 | 168 | 0.040 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 125 | 0.040 |
Why?
| | Femur Neck | 1 | 2020 | 62 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2023 | 592 | 0.040 |
Why?
| | Diffusion | 1 | 2000 | 120 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2020 | 178 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2021 | 265 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2021 | 214 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2021 | 280 | 0.040 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 221 | 0.040 |
Why?
| | Chromans | 1 | 1999 | 25 | 0.040 |
Why?
| | Immunoglobulin E | 1 | 2021 | 315 | 0.040 |
Why?
| | Retinoid X Receptors | 1 | 1999 | 42 | 0.040 |
Why?
| | Receptors, Retinoic Acid | 1 | 1999 | 44 | 0.040 |
Why?
| | Physicians, Women | 1 | 2020 | 90 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2020 | 251 | 0.040 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2021 | 592 | 0.040 |
Why?
| | Oleic Acid | 1 | 1999 | 40 | 0.040 |
Why?
| | 3T3 Cells | 1 | 1999 | 156 | 0.040 |
Why?
| | Gene Frequency | 1 | 2020 | 489 | 0.040 |
Why?
| | Dimerization | 1 | 1999 | 189 | 0.040 |
Why?
| | Biological Transport | 1 | 2000 | 424 | 0.030 |
Why?
| | Antibodies, Viral | 1 | 2023 | 674 | 0.030 |
Why?
| | Base Sequence | 2 | 1999 | 2171 | 0.030 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1998 | 92 | 0.030 |
Why?
| | Interleukins | 1 | 2020 | 248 | 0.030 |
Why?
| | Nutritional Status | 1 | 2021 | 353 | 0.030 |
Why?
| | Thiazoles | 1 | 1999 | 142 | 0.030 |
Why?
| | Minority Groups | 1 | 2020 | 285 | 0.030 |
Why?
| | Career Choice | 1 | 2020 | 235 | 0.030 |
Why?
| | Tretinoin | 1 | 1999 | 125 | 0.030 |
Why?
| | Lumbar Vertebrae | 1 | 2020 | 252 | 0.030 |
Why?
| | Peer Group | 1 | 2020 | 256 | 0.030 |
Why?
| | Pelvic Bones | 1 | 2020 | 134 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2021 | 572 | 0.030 |
Why?
| | Universities | 1 | 2020 | 445 | 0.030 |
Why?
| | Postmenopause | 1 | 2020 | 394 | 0.030 |
Why?
| | Quantitative Trait Loci | 1 | 2020 | 381 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 1999 | 2883 | 0.030 |
Why?
| | Collagen | 1 | 2020 | 457 | 0.030 |
Why?
| | ROC Curve | 1 | 2019 | 618 | 0.030 |
Why?
| | Social Media | 1 | 2020 | 167 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 644 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 442 | 0.030 |
Why?
| | Neoplasms | 1 | 2012 | 2913 | 0.030 |
Why?
| | Gestational Age | 1 | 2020 | 989 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2021 | 892 | 0.030 |
Why?
| | Occupational Exposure | 1 | 2020 | 355 | 0.030 |
Why?
| | Nuclear Respiratory Factor 1 | 1 | 2015 | 3 | 0.030 |
Why?
| | Anxiety | 1 | 2023 | 1122 | 0.030 |
Why?
| | Up-Regulation | 1 | 1999 | 848 | 0.030 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2015 | 39 | 0.030 |
Why?
| | Societies, Medical | 1 | 2020 | 900 | 0.030 |
Why?
| | Social Support | 1 | 2020 | 651 | 0.030 |
Why?
| | Electron Transport Complex IV | 1 | 2015 | 61 | 0.030 |
Why?
| | Insulin Antibodies | 1 | 2016 | 103 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2021 | 777 | 0.030 |
Why?
| | Prevalence | 1 | 2023 | 2874 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2023 | 1582 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2018 | 423 | 0.030 |
Why?
| | Risk | 1 | 2018 | 923 | 0.030 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 391 | 0.030 |
Why?
| | Nitric Oxide Synthase | 1 | 2015 | 234 | 0.030 |
Why?
| | Coronavirus Infections | 1 | 2020 | 384 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 693 | 0.030 |
Why?
| | Parents | 1 | 2023 | 1407 | 0.030 |
Why?
| | Chronic Disease | 1 | 2021 | 1812 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 1330 | 0.030 |
Why?
| | Sex Factors | 1 | 2020 | 2110 | 0.030 |
Why?
| | Mitochondrial Proteins | 1 | 2015 | 263 | 0.020 |
Why?
| | Family | 1 | 2018 | 685 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3416 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1547 | 0.020 |
Why?
| | DNA | 1 | 1999 | 1437 | 0.020 |
Why?
| | Glucose Clamp Technique | 1 | 2012 | 199 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1711 | 0.020 |
Why?
| | Physicians | 1 | 2020 | 956 | 0.020 |
Why?
| | Cell Differentiation | 1 | 1999 | 2050 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2026 | 11793 | 0.020 |
Why?
| | Haplotypes | 1 | 2012 | 500 | 0.020 |
Why?
| | Minnesota | 1 | 2010 | 168 | 0.020 |
Why?
| | Middle Aged | 3 | 2020 | 36302 | 0.020 |
Why?
| | Cytokines | 1 | 2017 | 2069 | 0.020 |
Why?
| | Fatty Liver | 1 | 2009 | 253 | 0.020 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2009 | 188 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2009 | 560 | 0.010 |
Why?
| | Metabolic Syndrome | 1 | 2009 | 361 | 0.010 |
Why?
| | Sequence Analysis | 1 | 1999 | 34 | 0.010 |
Why?
| | COS Cells | 1 | 1999 | 177 | 0.010 |
Why?
| | Aged | 1 | 2020 | 26215 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 1998 | 538 | 0.010 |
Why?
| | Introns | 1 | 1998 | 256 | 0.010 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 1998 | 328 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 1998 | 507 | 0.010 |
Why?
| | Exons | 1 | 1998 | 364 | 0.010 |
Why?
| | Alternative Splicing | 1 | 1998 | 248 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 1998 | 778 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 1998 | 1247 | 0.010 |
Why?
| | Protein Binding | 1 | 1998 | 2240 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2010 | 17325 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 1998 | 1454 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 1998 | 2601 | 0.000 |
Why?
|
|
Frohnert's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|